Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms

Estrogen‐Induced LncRNA, LINC02568, Promotes Estrogen Receptor‐Positive Breast Cancer Development and Drug Resistance Through Both In Trans and In Cis Mechanisms

Abstract Endocrine therapy is the frontline treatment for estrogen receptor (ER) positive breast cancer patients. However, the primary and acquired resistance to endocrine therapy drugs remain as a major challenge in the clinic. Here, this work identifies an estrogen‐induced lncRNA, LINC02568, which...

Full description

Bibliographic Details
Main Authors: Xue Chen, Jian‐cheng Ding, Guo‐sheng Hu, Xing‐yi Shu, Yan Liu, Jun Du, Zi‐jing Wen, Jun‐yi Liu, Hai‐hua Huang, Guo‐hui Tang, Wen Liu
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Advanced Science
Subjects:
ER‐positive breast cancer
estrogen and estrogen receptor
lncRNA
Online Access:https://doi.org/10.1002/advs.202206663

Internet

https://doi.org/10.1002/advs.202206663

Similar Items